应用组织芯片研究乳腺癌组织中CK5/6蛋白的表达及其临床意义

CK5/6 expression in human breast cancer with tissue micro-array and its clinical significance

目的探讨乳腺癌组织中CK5/6蛋白的表达与临床及预后的关系。方法制作240例乳腺癌组织芯片,采用免疫组织化学法检测乳腺癌组织中CK5/6蛋白的表达,分析其与乳腺癌临床病理特征及预后的关系。结果CK5/6阳性表达占乳腺癌总数的14.72%(29/197)。CK5/6表达与患者年龄、月经、肿瘤大小、TNM分期、淋巴结转移情况、肿瘤病理类型等无关,而与ER阴性表达具有相关性(P<0.01)。CK5/6表达阳性与阴性的乳腺癌比较,生存期短且预后差。结论CK5/6阳性表达的乳腺癌患者预后较差,CK5/6可成为乳腺癌预后的指标之一。

Objective： To explore the expression of CK5/6 in breast cancer, Methods The expression of CK5/6 in 240 breast carcinomas samples was determined by immunohistochemistry with tissue micro-array （TMA）, Results Positive expression ratio of CK5/6 in breast cancer was 14.72%（29/197）, CK5/6 expression was not correlated with age, menses, size of tumor, clinical TNM stage, auxiliary lymph nodes metastasis, or pathologic type（ P 〉 0.05）but was correlated with negative expression of ER; Patients with negative CK5/6 expression survived longer than those with positive expression（ P 〈 0.01）. Conclusions Positive expression of CK5/6 can result in In, or prognosis and it may be one of markers to evaluate the prognosis of breast cancer.